Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922602 | 0.91 | CHRM3 (0.68) | CHRM3 | |
| SCHEMBL1922419 | 0.90 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL1924455 | 0.90 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL1922949 | 0.90 | CHRM3 (0.66) | CHRM3 | |
| SCHEMBL3229187 | 0.89 | CHRM3 (0.59) | CHRM3 | |
| SCHEMBL1922817 | 0.89 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL1922575 | 0.87 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL1923277 | 0.86 | CHRM3 (0.66) | CHRM3 | |
| SCHEMBL1922591 | 0.86 | CHRM3 (0.63) | CHRM3 | |
| SCHEMBL1922141 | 0.86 | CHRM3 (0.63) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010007552-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.